Abstract: A chloroprene-unsaturated nitrile copolymer having 3 to 20% by mass of a structural unit derived from an unsaturated nitrile monomer, in which the chloroprene-unsaturated nitrile copolymer has a peak at 5.80 to 6.00 ppm in a 1H-NMR spectrum as measured in a deuterochloroform solvent, and a ratio (A/B) of a peak area (A) at 5.80 to 6.00 ppm and a peak area (B) at 4.05 to 6.20 ppm is 0.6/100 to 1.1/100.

Abstract: A chloroprene-unsaturated nitrile copolymer composition containing 100 parts by mass of a chloroprene-unsaturated nitrile copolymer having 3 to 20% by mass of a structural unit derived from an unsaturated nitrile monomer, and 0.05 to 2.0 parts by mass of a xanthogen compound.

Abstract: A hollow first accommodating case (28) is provided on a front part of a revolving frame (5) at a position on a front side of a fuel tank (23), and a fuel supply pump (34) for supplying a fuel stored in an external fuel storage source to the fuel tank (23) is provided on the fuel tank (23) by being connected. A fuel suction port (35) for sucking the fuel toward the fuel supply pump (34) is provided in the first accommodating case (28) by being opened to an outside, and a urea water tank (25) is provided by being accommodated in the first accommodating case (28). A water supply port (25G) of a urea water is provided in the urea water tank (25) by being opened to the outside, and the fuel suction port (35) and the water supply port (25G) of the urea water are juxtaposed and arranged in the first accommodating case (28).

Abstract: A hollow first accommodating case (28) is provided on a front part of a revolving frame (5) at a position on a front side of a fuel tank (23), and a fuel supply pump (34) for supplying a fuel stored in an external fuel storage source to the fuel tank (23) is provided on the fuel tank (23) by being connected. A fuel suction port (35) for sucking the fuel toward the fuel supply pump (34) is provided in the first accommodating case (28) by being opened to an outside, and a urea water tank (25) is provided by being accommodated in the first accommodating case (28). A water supply port (25G) of a urea water is provided in the urea water tank (25) by being opened to the outside, and the fuel suction port (35) and the water supply port (25G) of the urea water are juxtaposed and arranged in the first accommodating case (28).

Abstract: A hollow first accommodating case (28) is provided on a front part of a revolving frame (5) at a position on a front side of a fuel tank (23), and a fuel supply pump (34) for supplying a fuel stored in an external fuel storage source to the fuel tank (23) is provided on the fuel tank (23) by being connected. A fuel suction port (35) for sucking the fuel toward the fuel supply pump (34) is provided in the first accommodating case (28) by being opened to an outside, and a urea water tank (25) is provided by being accommodated in the first accommodating case (28). A water supply port (25G) of a urea water is provided in the urea water tank (25) by being opened to the outside, and the fuel suction port (35) and the water supply port (25G) of the urea water are juxtaposed and arranged in the first accommodating case (28).

Abstract: An input device includes an insulation substrate, a switch element, and a detection portion. The switch element includes a fixed electrode portion that is provided on the substrate, and a movable electrode portion that is provided on a main surface side of the substrate, at least part of the movable electrode portion being elastically displaceable toward a direction approaching and leaving the fixed electrode portion. The movable electrode portion is displaceable toward a direction approaching the fixed electrode portion due to pressure from an object to be detected that is an electric conductor. The detection portion is capable of detecting a capacitance change caused by the object to be detected approaching and leaving the movable electrode portion and a capacitance change between the movable electrode portion and the fixed electrode portion produced by displacement of the movable electrode portion due to pressing.

Abstract: An input device includes an insulation substrate, a switch element, and a detection portion. The switch element includes a fixed electrode portion that is provided on the substrate, and a movable electrode portion that is provided on a main surface side of the substrate, at least part of the movable electrode portion being elastically displaceable toward a direction approaching and leaving the fixed electrode portion. The movable electrode portion is displaceable toward a direction approaching the fixed electrode portion due to pressure from an object to be detected that is an electric conductor. The detection portion is capable of detecting a capacitance change caused by the object to be detected approaching and leaving the movable electrode portion and a capacitance change between the movable electrode portion and the fixed electrode portion produced by displacement of the movable electrode portion due to pressing.

Abstract: A reception apparatus includes: a reception unit configured to receive, from an information processing apparatus configured to distribute content, file data of the content transmitted in a file unit; a buffer configured to store the received file data; a change unit configured to change a bit-rate of the file data to be received; and a buffer control unit configured to delete, when the bit-rate is changed from a first bit-rate to a second bit-rate higher than the first bit-rate, file data other than files at least including a file being reproduced and a file to be next reproduced, out of the file data stored in the buffer.

Abstract: The present invention relates to a novel 3-aminobenzamide, compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide, compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathicpain, rheumatoid arthritis pain, and neuralgia.

Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

Abstract: To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound.

Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

Abstract: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

Abstract: To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound.

Abstract: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

Abstract: An RARP server receives ARP requests that application servers send when they get started. The RARP server records MAC addresses and IP addresses of the application servers. Thereafter, when a client terminal tries to execute an application and needs to access an application server, if the client terminal does not know an IP address of the application server, the client terminal broadcasts an RARP request that describes an MAC address of the application server and obtains an IP address of the application server from the RARP server. Thus, the client terminal accesses the server with the MAC address and IP address of the application server and performs a predetermined data communication.